TD Cowen analyst Dan Brennan lowered the firm’s price target on NeoGenomics (NEO) to $19 from $20 and keeps a Buy rating on the shares. The firm said they posted a rare quarterly shortfall and combined with the CEO transition, sent the shares lower. Although results were mixed, they believe the share price decline seems to be an over reaction.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics price target lowered to $16 from $19 at BofA
- NeoGenomics Achieves Double-Digit Revenue Growth in 2024
- NeoGenomics Q4 Earnings Call Highlights Growth Amid Challenges
- NeoGenomics: Overcoming Short-term Setbacks with Strategic Growth Initiatives and Leadership Transition
- Buy Rating Maintained for NeoGenomics Despite Mixed Results and Leadership Changes